Insider buying last 90 days
$54Kin 1 open-market purchase
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 27 | Anderson Woodrow D officer: Chief Accounting Officer | Purchase | $54K |
From Form 4 filings, dated to when each was filed.
Nov 9 close
Indivior's week centers on its completed merger with Supernus Pharmaceuticals, with the combined entity now trading under the Supernus name and ticker SUPN effective 3 November. Jack A. Khattar was appointed CEO and director, with four existing officers and four directors departing. This follows strong third-quarter results reported 29 October, with net revenue climbing 13% to $356 million, net income rising to $137 million from $42 million, and EPS of $1.32 topping estimates by $0.52; the company also issued FY2026 guidance projecting revenue between $1.29 billion and $1.36 billion.
The stock closed at $26.74, down 5.2%, sitting below both its 50-day average of $34.69 and 200-day average of $35.61, with the 50-day below the 200-day. Despite this technical headwind, the GekkoIndex sits at 90, placing it in the Buying zone, and the price is 29.2% below Gekko Fair Value of $37.75.
No further earnings are scheduled until 25 February 2027, keeping that catalyst outside a typical 20-trading-day hold. Smart money activity over the last 90 days includes one open-market insider purchase, alongside one billionaire holder and one trailblazer holder. Analyst coverage from 2 firms shows both rated buy, with a consensus target of $49.50. Seasonality over the next 20 trading days has averaged a 3% return across 4 years, though gains occurred in only 2 of those years.
Written by AI from the Nov 5, 2026 close and checked automatically against the figures on this page.
Indivior Pharmaceuticals scores 5 supportive, 0 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive0 mixed1 headwind
Below 50 and 200-day
Close $27.62 is below the 50-day ($34.36) and 200-day ($35.54) averages, and the 50-day is below the 200-day.
See the chart82.7, Buying
Reading 82.7 is in the Buying zone.
See the GekkoIndex26.8% below
Price is 26.8% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: 1 open-market insider purchase.
See smart moneyReports in 102 days
Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.
See earnings+10.5% on average
From this point in the calendar, the next 20 trading days averaged +10.5% over 4 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Indivior Pharmaceuticals closed at $27.62 on Nov 9, 2026, −13.3% over the past year, inside a 52-week range of $25.92 to $42.81.
Use the left and right arrow keys to read daily values.
Put INDV on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Indivior Pharmaceuticals develops, manufactures, and distributes buprenorphine-based medicines used in treating opioid dependence. Its lineup of prescription pharmaceuticals includes Suboxone Film, Suboxone Tablet, and Subutex Tablet, products aimed at patients managing opioid use disorder. These medicines represent the core of what the company is known for within its field of prescription treatment.
Indivior Pharmaceuticals is structured as a holding company overseeing the research, production, and distribution activities tied to these medications. It organizes its operations across distinct geographic segments, namely the United States, the United Kingdom, and a broader international market that spans other regions where its products reach patients and healthcare providers.
The company was established on September 26, 2014, and its corporate headquarters are situated in North Chesterfield, Virginia. Its shares are listed on the NASDAQ under the ticker INDV, allowing investors to trade ownership in the business through that exchange.
Indivior Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 82.7, in the Buying zone, up 29.9 points over five sessions.
Up 29.9 points over five sessions, from the Neutral zone.
Reading for Nov 9, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 55 | +2.7% | +7.3% | ||
| Accumulation | 194 | −0.2% | −2.7% | ||
| Neutral | 363 | +0.8% | +5.3% | ||
| Distribution | 80 | +2.6% | +5.8% | ||
| Selling | 6 | Too few readings yet | |||
Average INDV share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +2.9% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
Indivior Pharmaceuticals trades 26.8% below Gekko Fair Value of $37.75, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Indivior Pharmaceuticals shares are worth, recalculated every trading day.
$37.75
Gekko Fair Value, Nov 6, 2026
26.8% Undervalued
At the end of Aug 2026 the price was 23.4% below the estimate.
Insiders filed 1 open-market purchase in Indivior Pharmaceuticals worth $54K, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$54Kin 1 open-market purchase
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 27 | Anderson Woodrow D officer: Chief Accounting Officer | Purchase | $54K |
From Form 4 filings, dated to when each was filed.
No trades in INDV were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Indivior Pharmaceuticals has been buying back its own shares.
From company filings.
2of the funds Gekko tracks hold INDV.
Indivior Pharmaceuticals reports on Feb 25, 2027, before the open (102 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 25, 2027
Expected before the open, 102 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $1.32 est $1.06 | $356.0M est $329.4M | +1.7% |
| Aug 3, 2026 | $1.15 est $0.97 | $343.0M est $306.2M | −8.8% |
| Apr 30, 2026 | $0.96 est $0.66 | $317.0M est $272.8M | +10.3% |
| Feb 26, 2026 | $0.82 est $0.65 | $358.0M est $305.6M | −2.7% |
| Oct 30, 2025 | $0.72 est $0.38 | $314.0M est $306.2M | +16.4% |
| Jul 31, 2025 | $0.51 est $0.26 | $302.0M est $255.2M | +21.0% |
| Apr 24, 2025 | $0.41 est $0.22 | $266.0M est $242.3M | +22.3% |
| Feb 20, 2025 | $0.32 est $0.32 | $299.0M est $240.1M | −22.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Indivior Pharmaceuticals is $49.50, +79.2% from the last close, from 2 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 2 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 28 | Barclays | $45 | +62.9% |
| Sep 17 | Craig-Hallum | — | — |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Indivior Pharmaceuticals averaged +10.5% across the last 4 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.1% | 2 of 4 |
| Next 10 trading days | +6.5% | 3 of 4 |
| Next 15 trading days | +3.2% | 2 of 4 |
| Next 20 trading days | +10.5% | 3 of 4 |
| Next 30 trading days | +11.3% | 3 of 4 |
For scale, INDV’s typical 20-trading-day move in either direction is about 9.6%.
Indivior Pharmaceuticals’s market cap is $4.53B, with a P/E ratio of 10.2 and revenue of $1.37B over the last twelve months.
3 headlines about Indivior Pharmaceuticals from the past week, newest first, each linking to the publisher.
Indivior Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Indivior Pharmaceuticals’s market cap is $4.53B at the Nov 9, 2026 close of $27.62, with 118.0M shares outstanding. The shares trade on a P/E ratio of 10.2.
The consensus analyst 12-month price target for Indivior Pharmaceuticals is $49.50, +79.2% from the last close. Of the 2 firms that rated the stock in the last 90 days, 2 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Indivior Pharmaceuticals is undervalued: the Nov 9, 2026 close of $27.62 is 26.8% below Gekko Fair Value of $37.75. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Indivior Pharmaceuticals is expected to report on Feb 25, 2027, before the market opens (102 days away). Analysts expect earnings of $0.99 per share on revenue of $337.9M. Indivior Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 13.2% on average across the report.
Indivior Pharmaceuticals’s 52-week high is $42.81 and its 52-week low is $25.92; it closed at $27.62 on Nov 9, 2026, −13.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.